RedHill Biopharma (RDHL) Tops Q3 EPS by 16c

RedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of ($0.05), $0.16 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $24.52 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• SanDisk stock target lifted at Bernstein to $3000 on new memory LTAs
• AeroVironment (AVAV) PT Lowered to $280 at Canaccord
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations